Shanghai Yizhong Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 93.45%

Shanghai Yizhong Pharmaceutical Co., Ltd. Gross Profit Margin is 93.45% for the year ending December 31, 2023, a 0.69% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Shanghai Yizhong Pharmaceutical Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 92.81%, a 0.07% change year over year.
Shanghai Yizhong Pharmaceutical Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 92.75%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shanghai Stock Exchange: 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd.

CEO	Mr. Jingsong Zhou
IPO Date	Sept. 9, 2021
Location	China
Headquarters	No.79 Renqi Road
Employees	304
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It develops a dosage form of paclitaxel, an anti-tumor chemotherapeutic. The company was founded in 2009 and is based in Shanghai, China.

Key trends

Past 5 years